A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-24
DOI
10.1007/s12325-022-02042-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- COVID antibody treatments show promise for preventing severe disease
- (2021) Heidi Ledford NATURE
- A neutrophil activation signature predicts critical illness and mortality in COVID-19
- (2021) Matthew L. Meizlish et al. Blood Advances
- Experience with the use of siltuximab in patients with SARS-CoV-2 infection
- (2021) Fernanda Meira et al. Revista Espanola de Quimioterapia
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
- (2021) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Coronavirus infections and immune responses
- (2020) Geng Li et al. JOURNAL OF MEDICAL VIROLOGY
- Reducing mortality from 2019-nCoV: host-directed therapies should be an option
- (2020) Alimuddin Zumla et al. LANCET
- IKKβ overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice
- (2020) Angustias Page et al. International Journal of Oral Science
- Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
- (2020) Yonggang Zhou et al. National Science Review
- Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
- (2020) Bingwen Liu et al. JOURNAL OF AUTOIMMUNITY
- Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial
- (2020) Bastiaan Maes et al. Trials
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19
- (2020) Enrico Brunetta et al. NATURE IMMUNOLOGY
- Pentraxin 3: Potential prognostic role in SARS-CoV-2 patients admitted to the emergency department
- (2020) Annalisa Schirinzi et al. JOURNAL OF INFECTION
- Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
- (2019) Lara L. Riegler et al. Therapeutics and Clinical Risk Management
- Targeting Interleukin-6 Signaling in Clinic
- (2019) Sujin Kang et al. IMMUNITY
- Diagnosis and Management of Castleman Disease
- (2019) Jeremy S. Abramson Journal of the National Comprehensive Cancer Network
- Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis
- (2018) Yvette N. Lamb et al. DRUGS
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
- (2018) Ali Berkant Avci et al. BIODRUGS
- Tocilizumab (Actemra)
- (2017) Martin Sheppard et al. Human Vaccines & Immunotherapeutics
- Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
- (2016) Sylvia Heink et al. NATURE IMMUNOLOGY
- Dose selection of siltuximab for multicentric Castleman’s disease
- (2015) Christina L. Mayer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Interleukin-6: Biology, signaling and strategies of blockade
- (2015) Fred Schaper et al. CYTOKINE & GROWTH FACTOR REVIEWS
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
- (2015) Frits van Rhee et al. Oncotarget
- Exploiting interleukin 6 in multicentric Castleman's disease
- (2014) Mark Bower et al. LANCET ONCOLOGY
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Maximum-Tolerated Dose, Optimum Biologic Dose, or Optimum Clinical Value: Dosing Determination of Cancer Therapies
- (2012) John L. Marshall JOURNAL OF CLINICAL ONCOLOGY
- The interleukin 6 pathway and atherosclerosis
- (2012) Jürgen Scheller et al. LANCET
- IL-6/IL-6 receptor system and its role in physiological and pathological conditions
- (2011) Masahiko Mihara et al. CLINICAL SCIENCE
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
- (2010) T. Puchalski et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started